Q32 Bio Inc (QTTB)

May 8, 2025, 6:59 AM EDT - 5 days ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 30, 2025, 6:59 AM EDT - 13 days ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 27 days ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Mar 11, 2025, 6:59 AM EDT - 2 months ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 8, 2025, 11:00 AM EST - 2 months ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Feb 28, 2025, 9:00 AM EST - 2 months ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 26, 2025, 6:59 AM EST - 2 months ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 10, 2025, 4:05 PM EST - 3 months ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 4, 2025, 4:05 PM EST - 3 months ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Dec 11, 2024, 11:32 AM EST - 5 months ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 10, 2024, 4:05 PM EST - 5 months ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Nov 7, 2024, 6:59 AM EST - 6 months ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 6:59 AM EST - 6 months ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Oct 14, 2024, 6:59 AM EDT - 7 months ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Aug 29, 2024, 6:59 AM EDT - 9 months ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 3:40 AM EDT - 9 months ago

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 1, 2024, 4:54 PM EDT - 10 months ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

AIU COMM EBS HE HUMA SAVA SERV

Jul 9, 2024, 6:59 AM EDT - 11 months ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 1, 2024, 6:59 AM EDT - 11 months ago

Q32 Bio Joins Russell 3000® Index

May 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Mar 25, 2024, 4:15 PM EDT - 1 year ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million